GENERAL DISCLOSURES

This marketing communication (hereinafter also the “communication”) is prepared by an internal department of Mediobanca - Banca di credito finanziario S.p.A. (“Mediobanca S.p.A.”), authorized and supervised by the Bank of Italy and Consob to provide financial services, and constitutes a set of information produced by persons other than an independent analyst which recommend a particular investment decision in respect of a financial instrument, as defined by the relevant European regulation directive provisions on market abuse (MAR Regulation).

This communication is deemed not to be an investment research as defined by the relevant European Directive provisions on investment and ancillary services (MiFID Directive) and by the implementing law. This marketing communication is not prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This marketing communication is not directed at you if Mediobanca S.p.A. is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Mediobanca S.p.A. is permitted to provide communications concerning investments to you under relevant legislation and regulations. Mediobanca S.p.A. accepts no responsibility whatever for any failure by a person resident outside the European Union to observe the foregoing.

This communication is provided for information purposes only and does not constitute or should not be construed as a provision of investment advice, an offer to buy or sell, or a solicitation of an offer to buy or sell, any financial instruments. It is not intended to represent the conclusive terms and conditions of any security or transaction, nor to notify you of any possible risks, direct or indirect, in undertaking such a transaction. Not all investment strategies are appropriate at all times, and past performance is not necessarily a guide to future performance. Mediobanca S.p.A. recommends that independent advice should be sought, and that investors should make their own independent decisions as to whether an investment or instrument is proper or appropriate based on their own individual judgment, their risk-tolerance, and after consulting their own investment advisers.

The information contained herein, including any expression of opinion, has been obtained from or is based upon sources believed to be reliable but is not guaranteed as to accuracy or completeness although Mediobanca S.p.A. considers it to be fair and not misleading. Neither Mediobanca S.p.A. nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error, inaccuracy or incompleteness of fact or opinion in this marketing communication or lack of care in its preparation or publication.

COPYRIGHT NOTICE

No part of the content of this communication may be copied, forwarded or duplicated in any form or by any means without the prior consent of Mediobanca S.p.A., and Mediobanca S.p.A. accepts no liability whatsoever for the actions of third parties in this respect.
AGENDA

1. Developments Since Last BMCG Meeting
2. Market Prospects
   2.a 3 Risks and 1 Strong Uncertainty
   2.b Market Perspective
3. Discussion Points
   3.a What if EUR Strength/USD weakness is Structural?
   3.b Few More Issues for Discussion
DEVELOPMENTS SINCE LAST BMCG MEETING

Section 1
2 Major Structural Changes and CARES Expiry *(1/2)*

**Developments Since Last BMCG Meeting**

**Next Generation EU (18 May - 21 July)**
- The process begins with the Franco-German proposal on May the 18th. It ends on July 21st.
- Main features
  - **EUR 390bn grants** allow targeted and one-off fiscal transfers among member states
  - **A Supra national European bond issuer becomes market-material**
  - Not clear if there is a “joint and several guarantee” of members states

**Flexible Average Inflation Targeting (27 August)**
- Main features
  - It allows for **time limited inflation target overshoots following below target spells.**
  - Fed shifts from proactive to reactive
  - It (only) incentivizes the market to price above target future inflation
  - No change in FED’s toolbox

**CARES (1) Expiry (25 July)**
- CARES starts on March the 27th and ends on July 25th.
- Main features
  - **USD 2tr grants** capacity
  - Extremely granular program
  - Households disposable income rose significantly (by USD 1tr from Feb to Jul) despite a large wage drop (by USD 445bn from Feb to Jul)

---

(1) CARES (= Coronavirus Aid, Relief, and Economic Security) is centered on up to USD 1.2k per adult making less than USD 99k/Y and USD 500 per child under 17 + USD 1.2k to no-2018-2019-tax filers Social Security recipients

---

**US Disp. Income (white); Wages (gold); USD bn**
The process that saw Next Generation EU born boosted confidence in the EU project =>
- stronger EUR (and weaker USD from multi year strength),
- US equity outperforms EU equities
- synchronized credit spread contraction both in periphery and core countries in Euro area
- credit risk term structure broad brush unchanged over the period

CARES expiry and AIT are so far mkt irrelevant

Note: White shaded spell is May 18 (Franco-German recovery fund proposal) to Jul 21 (Next Generation EU approved), red vertical is Jul 25 (end of CARES), green vertical line is Aug 27 (AIT speech by Mr. Powell)
1) 10-2 IT BOX = 10Y (IT – GER) - 2Y (IT – GER); 10-2 FR BOX = 10Y (FR – GER) - 2Y (FR – GER)
Market Prospects

Section 2
3 Risks and 1 Strong Uncertainty

Subsection 2.a
3 Risks: Fiscal Stimulus, Election Day, UK-EU Trade Deal

3 Risks and 1 Strong Uncertainty

US Financial Stimulus Renewal: global relevant

- **To Reps**, households making more money via subsidies than jobs is unconceivable => USD 0.5tr stimulus proposal
- **To Dems**, inefficiencies are worth paying to sustain households income => USD 2.2tr stimulus proposal
- The latest attempt to bridge the differences is a bipartisan caucus proposal worth some USD 1.5tr
- The information set on this issue is stable => solution pops in a short time or after the elections

US Presidential elections: global relevant

- Mr. Trump has proclaimed his discontent with mailed ballots
- He will not concede if mail-ballots are deemed crucial for Mr. Biden’s victory
  - By Dec 8th States votes disputes need to be solved; electors cast their vote on Dec 14th. Congress counts the votes on Jan 6th. If disagreement persists to Jan 20 the speaker of the House would act as caretaker
- The stalemate after the last contested election result lived up to mid Dec

EU-UK Trade deal: “regional” relevant

- The UK seeks ways to access the EU single market, tax/subsidize domestic economic sectors at will, and preserve the Good Friday agreement
- The EU would allow access to the single market only if the UK commits not to subsidize some industries and apply EU regulation (for this would disrupt market competition)
- No-deal Brexit is becoming the “bad equilibrium”

When a USD 750 billion or more of fiscal stimulus?
Red: 1 Aug to 31 Oct; yellow 1 Nov to 31 Dec; green: Later

Source: Good Judgement. As of Sep 17, 2020 1 Aug to 31 Oct = 31%; 1 Nov to 31 Dec = 12%; Later = 57%
1 Strong Uncertainty: COVID-19 Vaccine

3 Risks and 1 Strong Uncertainty

C19 Vaccine: global relevant

- Grand total of **55 candidate vaccines are being developed**
- 9 in pre-approval phase, 5 are being utilized without approval
- **Strong uncertainty about whether/when a candidate vaccine will be approved**
- Possible production hurdles
  - How many doses to each individual? Guesstimates for deployment in 1st quarter past approval are in 2 to 4bn doses range
  - Storage capacity
  - Adjuvant (a vaccine booster) production
  - Vials production capacity, as pre-stocking is not viable before knowing the vaccine properties
  - Syringes production
- **Bottom line**
  - A vaccine may or may not be developed: strong uncertainty
  - It’s entirely plausible, but not sure, a vaccine will be ready by year end
  - Vaccine approval will flare market sentiment
  - Past approval, effective medical treatment will take a few quarters to spread globally

Source: NY Times and Bloomberg
Note, ph 1 = vaccine tested in small numbers, it checks safety and dos; ph 2 = 100s of people tested, it checks for vaccine’s stability among sub-groups; ph 3 = 1,000s tested, placebo introduced, it checks vaccine’s protection (defined by the public health authority); Lim Usage = emergency use, approval = vaccine is approved by the competent authority, monitoring for safety continues.
Market Perspective

Subsection 2.b
**Real Economy Needs Low Rates**

**Market Perspective**

- **10Y Nom US (yellow, 22d Mav is bold), 10Y Nom Germany (white, 22d MAv is bold)**
  - [Graph showing bond yields]

- **10Y Real US (yellow, 22d Mav is bold), 10Y Real Germany (white, 22d MAv is bold)**
  - [Graph showing real bond yields]

**Delta Debt/GDP (%): World (blue); EA (grey); US (gold)**

- Government debt jumped due to C19 policy response
- Low nominal yields are needed to keep cost of funding in check
- Low real yields are needed to pinpoint fixed capital formation and future growth

Source: IMF, WEO
Currency hedged yields generally offer no effective alternative to domestic bonds.

Exception: Euro Area periphery (e.g., Italy and Spain) yields stand out from different jurisdictions.

Barring risk-off flares, yield hunting is likely to lure investors towards Euro Area periphery.
DISCUSSION POINTS

Section 3
**What if EUR Strength/USD Weakness is Structural?**

**Discussion Points**

- Shaded area = from ECB announces “preparatory work” on QE (Jun14) to ECB starts QE (Mar15) =>
  - EUR weakens by some 18% to 1.11
  - Inflation expectations decrease
  - Core and headline inflation decrease
- Rule of thumb\(^{(3)}\): 1% EUR appreciation => slightly less than 0.1% lower EU inflation
- Sep 2020 ECB Staff Projections assume EUR at 1.18 in 2021 and 2022 and see inflation at 1.0% in 2021 and 1.3% in 2022

**What if EUR is in for structural appreciation?**

- USD reserve currency status is challenged (e.g. Ch diversifies away from it by selling treasuries and buying commodities)
- EU deeper integration (e.g. Next Generation EU)
- EUR could reach 1.25 (5% appreciation) and then 1.4 (18%) => roughly 0.5% off inflation or outright deflation respectively
- What’s the right response? Lower short term rates or further QE?
Few More Issues for Discussion

Discussion Points

- Is the fiscal dominance issue not market-relevant?
  - Debt will rise significantly in 2020 and 2021. Higher cost of debt weaken financial stability. Weakened financial stability impedes the transmission of monetary policy impulses.
  - Conclusion: Central banks are bound to buy government bonds to strengthen financial stability and tame debt costs.
  - Excerpt from Mrs. Schnabel recent speech(1) “Fiscal expansion is indispensable at the current juncture to sustain demand […]. Monetary policy can complement these efforts. But by itself, it may not be sufficient to stabilise the economy.” From a market perspective, this translates in 1) more fiscal stimulus is needed and 2) fiscal dominance is ok-sh

- Deglobalization incentivizes trade barriers. Is free movement of financial capital compatible with trade barriers? Are we entering a world where financial flows become, willingly or unwillingly, a policy issue? (e.g. EUR at 1.4, CHF at 1.00)

- The FED did change its reaction function but it did not change its toolbox. What other tool could the Fed/other CBs introduce to induce inflation ana not just wait for inflation to happen?

Debt/GDP (%): World (blue); EA (grey); US (gold)

Trade Volume (y/y, %)

---

(1) “The shadow of fiscal dominance: Misconceptions, perceptions and perspectives”, September, 2020
CONTACTS

Fabio Noacco
Group Economic and Macro Strategy
Mediobanca – Banca di Credito Finanziario

fabio.noacco@mediobanca.com